|
RAD9B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.53499998770224E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.32230046093696E-10 |
| Normal-vs-Stage2 |
1.02050035089007E-10 |
| Normal-vs-Stage3 |
4.07510025723923E-10 |
| Normal-vs-Stage4 |
2.70319988615597E-10 |
| Stage1-vs-Stage2 |
9.695500E-02 |
| Stage1-vs-Stage3 |
5.787800E-01 |
| Stage1-vs-Stage4 |
3.653400E-01 |
| Stage2-vs-Stage3 |
2.843000E-01 |
| Stage2-vs-Stage4 |
5.240000E-01 |
| Stage3-vs-Stage4 |
6.794400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.33880004252285E-09 |
| Normal-vs-AfricanAmerican |
5.46199999673647E-08 |
| Normal-vs-Asian |
2.53220000523413E-09 |
| Caucasian-vs-AfricanAmerican |
4.298000E-01 |
| Caucasian-vs-Asian |
4.397800E-01 |
| AfricanAmerican-vs-Asian |
8.618600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.42370046044505E-10 |
| Normal-vs-Female |
2.08559947090237E-10 |
| Male-vs-Female |
6.578000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.81490000805695E-09 |
| Normal-vs-Age(41-60Yrs) |
1.39249944908215E-10 |
| Normal-vs-Age(61-80Yrs) |
3.23280291425476E-11 |
| Normal-vs-Age(81-100Yrs) |
3.358400E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.056640E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.883910E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.942230E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.784400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.009040E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.407700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.386800E-01 |
| Classical-VS-Follicular |
2.77259999958979E-07 |
| Classical-VS-Other |
4.175600E-01 |
| Classical-VS-Normal |
7.25909998777752E-09 |
| Tall-VS-Follicular |
5.049600E-02 |
| Tall-VS-Other |
5.270000E-01 |
| Tall-VS-Normal |
9.43580003021083E-09 |
| Follicular-VS-Other |
7.006800E-01 |
| Follicular-VS-Normal |
2.4150681454671E-12 |
| Other-VS-Normal |
2.938400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.49160017670624E-10 |
| Normal-vs-N1 |
2.81409995306348E-09 |
| N0-vs-N1 |
3.787400E-01 |
|
|
